Contact

Category: Anti-Kickback/Stark

Posted in
Posted in

FCA Case Spotlight: District of Massachusetts Finds Insufficient Evidence of Remuneration or Willfulness in Janssen’s Infusion-Suite Support Programs

By 0 on FCA Case Spotlight: District of Massachusetts Finds Insufficient Evidence of Remuneration or Willfulness in Janssen’s Infusion-Suite Support Programs

United States ex rel. Long v. Janssen Biotech, Inc., No. 1:16-cv-12182-FDS, 2026 WL 2949353 (D. Mass. Sept. 30, 2026) Healthcare / False Claims Act · Anti-Kickback Statute · Manufacturer Practice Support · Scienter Introduction Manufacturers of physician-administered drugs have long supported the practices that administer them, with reimbursement hotlines, coding guides, nurse training, and advice […]

CONTINUE READING FCA Case Spotlight: District of Massachusetts Finds Insufficient Evidence of Remuneration or Willfulness in Janssen’s Infusion-Suite Support Programs 13 min read
Posted in
Posted in

Healthcare Case Spotlight: The D.C. Circuit Joins the Broad Reading of the Anti-Kickback Statute — and Strikes OIG’s Advisory-Opinion Timing Rules

By 0 on Healthcare Case Spotlight: The D.C. Circuit Joins the Broad Reading of the Anti-Kickback Statute — and Strikes OIG’s Advisory-Opinion Timing Rules

Vertex Pharmaceuticals Incorporated v. United States Department of Health and Human Services, No. 25-5133, ___ F.4th ___, 2026 WL 2617588 (D.C. Cir. Sept. 4, 2026) | affirming in part and reversing in part Vertex Pharms. Inc. v. U.S. Dep’t of Health & Hum. Servs., 774 F. Supp. 3d 211 (D.D.C. 2025) Healthcare / Anti-Kickback Statute […]

CONTINUE READING Healthcare Case Spotlight: The D.C. Circuit Joins the Broad Reading of the Anti-Kickback Statute — and Strikes OIG’s Advisory-Opinion Timing Rules 11 min read
Contact